Martijn Figee, MD
Psychiatry · New York, NYNPI 1477196822
Payments from drug & device makers
Across 166 payments — averaging $1163.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$178K
- Livanova USA, Inc.$7K
- Medtronic$5K
- Neurocrine Biosciences, Inc.$2K
- Acadia Pharmaceuticals Inc$1K
- Boston Scientific$255
- plus $239 from 2 others
What the payments were for
- Consulting fees$14,30045%
- Speaking & faculty fees$7,90025%
- Travel & lodging$3,0119%
- Food & beverage$6,66821%
- Education$870%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 71 | $177,968 |
| Livanova USA, Inc. | 6 | $6,691 |
| Medtronic(2 entities) | 33 | $4,774 |
| Neurocrine Biosciences, Inc. | 19 | $2,218 |
| Acadia Pharmaceuticals Inc | 33 | $1,069 |
| Boston Scientific | 2 | $255 |
| Insightec,inc | 1 | $177 |
| Neuronetics, Inc. | 1 | $62 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INFINITY$15,313
- VNS Therapy Symmetry Model 8103 Generator$6,543
- PERCEPT PC BRAINSENSE$3,471
- INGREZZA$2,073
- PROCLAIM$751
- NUPLAZID$473
- Exablate$177
- VNS - Symmetry$110
- GENERAL DBS$104
How this compares
$193,215 in reported general payments places this provider in the 95th percentile of 3,713 psychiatry providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Asenapine Maleate | 15 | $10,638 |
| Rivastigmine | 32 | $5,082 |
| RivastigmineRivastigmine Tartrate | 75 | $3,468 |
| Quetiapine Fumarate | 103 | $2,122 |
| Bupropion XlBupropion Hcl | 47 | $1,277 |
| Escitalopram Oxalate | 117 | $1,256 |
| Memantine Hcl | 28 | $1,197 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 34 | $1,088 |
| Clozapine | 13 | $1,045 |
| Bupropion Hcl | 46 | $860 |
| Divalproex Sodium ErDivalproex Sodium | 12 | $843 |
| Mirtazapine | 30 | $747 |
| Clonazepam | 75 | $531 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 12 | $464 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 19 | $431 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in New York
- Michael LiebowitzNew York$7.1M
- Paul EderNew York$2.7M
- Lenard AdlerNew York$1.8M
- Ram ShrivastavaNew York$1.8M
- Jonathan KaneNew York$1.8M
- Eric HollanderNew York$1.4M
- William HapworthNew York$1.3M
- Manish ZinzuvadiaNew York$1.3M
- Jianping ChenNew York$1.2M
- Anthony ZoghbiNew York$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.